Shandong Xinhua Pharmaceutical Company Limited (000756.SZ)
CNY 15.85
(0.38%)
CNY 15.85
(0.38%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 273.44 Million | 758.24 Million | 259.11 Million | 420.18 Million | 348.27 Million | 344.6 Million |
| Net Income | 496.51 Million | 426.31 Million | 362.07 Million | 347.11 Million | 323.11 Million | 274.28 Million |
| Depreciation & Amortization | 520.25 Million | 484.8 Million | 434.32 Million | 385.39 Million | 344.62 Million | 302.33 Million |
| Deferred income taxes | 6.04 Million | 20.01 Million | 13.71 Million | 22.84 Million | 13.3 Million | 23.13 Million |
| Stock-based compensation | 53.06 Million | 46.36 Million | 3.96 Million | 8.27 Million | 8.36 Million | 69.7 Thousand |
| Change in working capital | -876.79 Million | -265.39 Million | -539.55 Million | -362.78 Million | -423.71 Million | -316.65 Million |
| Other non-cash items | 2.04 Billion | 46.13 Million | -15.4 Million | 19.34 Million | 82.57 Million | 84.64 Million |
| Investing Cash Flow | -313.27 Million | -228.9 Million | -237.69 Million | -298 Million | -412.93 Million | -398.34 Million |
| Investments in PPE | -325.13 Million | -244.75 Million | -249.22 Million | -280.18 Million | -366.51 Million | -385.98 Million |
| Acquisitions | 11.85 Million | 45.31 Million | 19.82 Million | 283.78 Million | 369.33 Million | 6.51 Million |
| Investment purchases | - | -45.31 Million | -19.82 Million | -30 Million | -56.76 Million | -19.62 Million |
| Sales/Maturities of investments | 8.16 Million | 7.91 Million | 9.1 Million | 8.58 Million | 7.51 Million | 7.15 Million |
| Other Investing Activities | -8.16 Million | 7.93 Million | 2.42 Million | -280.18 Million | -366.51 Million | -6.39 Million |
| Financing Cash Flow | -196.1 Million | -130.65 Million | -139.72 Million | 35.03 Million | -46.23 Million | 44.52 Million |
| Debt repayment | -25.72 Million | -888.67 Million | -559.73 Million | -729.65 Million | -1.1 Billion | -267.83 Million |
| Dividends payments | -134.93 Million | -100.44 Million | -94.1 Million | -74.62 Million | -62.18 Million | -89.79 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -35.45 Million | 921.02 Million | 568.44 Million | 891.54 Million | 1.17 Billion | 402.15 Million |
| Accounts receivables | -423.54 Million | -717.32 Million | -751.07 Million | -683.3 Million | -301.06 Million | -416.85 Million |
| Accounts payables | -332.38 Million | 632.05 Million | 121.62 Million | 260.19 Million | 66.93 Million | 312.7 Million |
| Inventory | -120.86 Million | -200.14 Million | 76.17 Million | 37.47 Million | -202.89 Million | -263.36 Million |
| Other working capital | -1.00 | 20.01 Million | 13.71 Million | 22.84 Million | 13.3 Million | -53.28 Million |
| Cash at beginning of period | 1.15 Billion | 596.39 Million | 722.56 Million | 577.62 Million | 687.24 Million | 682.86 Million |
| Cash at end of period | 918.33 Million | 1.01 Billion | 596.39 Million | 722.56 Million | 577.62 Million | 679.45 Million |
| Capital Expenditure | -325.13 Million | -244.75 Million | -249.22 Million | -280.18 Million | -366.51 Million | -385.98 Million |
| Effect of forex changes on cash | 6.85 Million | 15.69 Million | -7.86 Million | -12.27 Million | 1.28 Million | 5.8 Million |
| Net cash flow / Change in cash | -240.4 Million | 414.37 Million | -126.17 Million | 144.93 Million | -109.61 Million | -3.4 Million |
| Free Cash Flow | -51.68 Million | 513.48 Million | 9.88 Million | 139.99 Million | -18.24 Million | -41.37 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 78.67 Million | 123.52 Million | 141.87 Million | 496.51 Million | 104.54 Million | 122.16 Million |
| Depreciation & Amortization | - | 133.87 Million | 133.87 Million | 520.25 Million | 131.34 Million | -254.79 Million |
| Deferred income taxes | - | - | - | 6.04 Million | 438.26 Million | 107.68 Million |
| Stock-based compensation | - | - | - | 53.06 Million | 53.06 Million | -27.36 Million |
| Change in working capital | - | - | - | -876.79 Million | -491.33 Million | 171.4 Million |
| Other non-cash items | 106.34 Million | 49.68 Million | -103.81 Million | 2.04 Billion | -46.85 Million | -62.98 Million |
| Investing Cash Flow | -44.14 Million | -44.15 Million | -52.47 Million | -313.27 Million | -124.67 Million | -67.68 Million |
| Investments in PPE | -52.54 Million | -44.62 Million | -52.52 Million | -325.13 Million | -124.53 Million | -80.69 Million |
| Acquisitions | 211.04 Thousand | 472.38 Thousand | 46.1 Thousand | 11.85 Million | -137.92 Thousand | 9.94 Million |
| Investment purchases | - | - | - | - | - | -9.94 Million |
| Sales/Maturities of investments | - | - | - | 8.16 Million | - | 3.06 Million |
| Other Investing Activities | 8.39 Million | 472.38 Thousand | 46.1 Thousand | -8.16 Million | -1.00 | 9.94 Million |
| Financing Cash Flow | 58.49 Million | 59.86 Million | 16.78 Million | -196.1 Million | 11.82 Million | -142.56 Million |
| Debt repayment | -255.46 Million | -66.96 Million | -23.03 Million | -25.72 Million | -380.66 Million | -68.58 Million |
| Dividends payments | -196.72 Million | -8.59 Million | -8.98 Million | -134.93 Million | -134.93 Million | -144.34 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -249.45 Thousand | -7.09 Million | 58.78 Million | -35.45 Million | 527.42 Million | 70.36 Million |
| Accounts receivables | - | - | - | -423.54 Million | -423.54 Million | 370.32 Million |
| Accounts payables | - | - | - | -332.38 Million | - | 27.36 Million |
| Inventory | - | - | - | -120.86 Million | -120.86 Million | -198.91 Million |
| Other working capital | - | - | - | -1.00 | 53.06 Million | -27.36 Million |
| Cash at beginning of period | 850.92 Million | 922.05 Million | 781.68 Million | 1.15 Billion | 824.28 Million | 854.29 Million |
| Cash at end of period | 1.04 Billion | 996.33 Million | 788.24 Million | 918.33 Million | 918.33 Million | 701.72 Million |
| Capital Expenditure | -52.54 Million | -44.62 Million | -52.52 Million | -325.13 Million | -124.53 Million | -80.69 Million |
| Effect of forex changes on cash | 877.06 Thousand | 7.62 Million | 4.18 Million | 6.85 Million | 3.77 Million | 1.55 Million |
| Net cash flow / Change in cash | 192.06 Million | 74.27 Million | 6.56 Million | -240.4 Million | 94.05 Million | -152.57 Million |
| Free Cash Flow | 132.48 Million | -5.28 Million | -14.45 Million | -51.68 Million | 64.49 Million | -24.58 Million |
0QPR
LUXIND
WBT
M&MFIN
1490
SACHEMT